Compare General Mills, Inc. (GIS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Smith & Nephew plc — how do they compare? General Mills, Inc. trades at $32.33 (market cap $17.43B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays the higher dividend (7.49%). Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Smith & Nephew plc for 121 Days on average.
| GIS | SNN | |
|---|---|---|
Market Cap | $17.43B | $11.10B |
Volume | 16,554,362 | 1,051,703 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $37.17 |
52-Week Low | $31.67 | $26.42 |
Typical Hold Time | 106 Days | 121 Days |
Enterprise Value | $30.61B | $14.13B |
Dividend Yield | 7.49% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.29, up 1.64% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.23 and P/S of 0.96. Recent Q2 2026 earnings beat expectations at $0.95 EPS versus $0.797 expected, though Q4 2025 missed. The company maintains dividend payments of $0.61 per share while facing profitability challenges with negative net income margin and ROE. Leadership transition is underway with Dana McNabb set to succeed Jeff Harmening as CEO.
Outlook remains cautious with analyst consensus at Hold (61%) and $36 price target. Key risks include declining revenue trends, margin pressure, and high debt levels at 45% of assets. The stock offers value appeal but requires successful execution of the $3B savings plan and turnaround strategy to drive sustainable growth amid competitive pressures.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
